Literature DB >> 12654087

Endemically exposed asymptomatic individuals show no increase in the specific Leishmania (Viannia) panamensis-Th1 immune response in comparison to patients with localized cutaneous leishmaniasis.

C M Trujillo1, S M Robledo, J L Franco, I D Velez, K J Erb, P J Patiño.   

Abstract

In Colombia, most cases of human cutaneous leishmaniasis are caused by Leishmania (Viannia) panamensis. Interestingly, up to 30% of the exposed population do not suffer from clinical leishmaniasis although it is likely that they are continuously infected with Leishmania parasites. Since it is believed that the induction of efficient Th1 immune responses protects against Leishmania infections both in humans and in animal models, we determined if endemically exposed asymptomatics showed stronger Leishmania-specific Th1 immune responses than patients with active localized cutaneous leishmaniasis (LCL). We found that Montenegro skin test responses were slightly higher among asymptomatic individuals compared to patients suffering from LCL. However, PBMC from patients with LCL showed similar Leishmania-specific proliferative responses compared to PBMC from asymptomatic individuals. Furthermore, PBMC from both groups also secreted similar amounts of IFN-gamma, IL-12p40 and IL-10 after in vitro exposure to L. panamensis. No IL-4 was detected in the supernatants. Taken together our results suggest that lack of LCL development in endemically exposed asymptomatics cannot be explained by stronger systemic anti-Leishmania Th1 immune responses or decreased Th2 responses in these individuals in comparison to individuals who develop LCL. It may be possible that other mechanisms are responsible for resistance to cutaneous leishmaniasis in Colombia in endemically exposed asymptomatics.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12654087     DOI: 10.1046/j.1365-3024.2002.00488.x

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  6 in total

1.  Murine model of chronic L. (Viannia) panamensis infection: role of IL-13 in disease.

Authors:  Tiago M Castilho; Karen Goldsmith-Pestana; Caterin Lozano; Liliana Valderrama; Nancy G Saravia; Diane McMahon-Pratt
Journal:  Eur J Immunol       Date:  2010-10       Impact factor: 5.532

2.  A Mouse Model of Ulcerative Cutaneous Leishmaniasis by Leishmania (Viannia) panamensis to Investigate Infection, Pathogenesis, Immunity, and Therapeutics.

Authors:  Natalia Muñoz-Durango; Alexander Gómez; Natalia García-Valencia; Miguel Roldán; Marcela Ochoa; David E Bautista-Erazo; José R Ramírez-Pineda
Journal:  Front Microbiol       Date:  2022-06-13       Impact factor: 6.064

3.  CD26 expression on CD4+T cells in patients with cutaneous leishmaniasis.

Authors:  R Jafari-Shakib; S Ajdary; Z Mohtasham Amiri; A M Mohammadi; K Nourijelyani; H Mortazavi; M A Shokrgozar; B Nikbin; A Khamesipour
Journal:  Clin Exp Immunol       Date:  2008-05-05       Impact factor: 4.330

4.  Dynamic analysis of Th1/Th2 cytokine concentration during antiretroviral therapy of HIV-1/HCV co-infected patients.

Authors:  Wenzhen Kang; Yuan Li; Yan Zhuang; Ke Zhao; Dedong Huang; Yongtao Sun
Journal:  BMC Infect Dis       Date:  2012-04-25       Impact factor: 3.090

5.  Macrophages participate in host protection and the disease pathology associated with Leishmania braziliensis infection.

Authors:  Angela Giudice; Célia Vendrame; Caroline Bezerra; Lucas P Carvalho; Thaís Delavechia; Edgar M Carvalho; Olívia Bacellar
Journal:  BMC Infect Dis       Date:  2012-03-29       Impact factor: 3.090

Review 6.  Asymptomatic infection with American cutaneous leishmaniasis: epidemiological and immunological studies.

Authors:  Fernando J Andrade-Narvaez; Elsy Nalleli Loría-Cervera; Erika I Sosa-Bibiano; Nicole R Van Wynsberghe
Journal:  Mem Inst Oswaldo Cruz       Date:  2016-10       Impact factor: 2.743

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.